Yasmine S. Makarem , Elzahraa A. Ahmed , Marwa Makboul , Shimaa Farghaly , Naima Mostafa , Randa A. El Zohne , Samar H. Goma
{"title":"作为类风湿性关节炎患者间质性肺病生物标记物的 CXCL10","authors":"Yasmine S. Makarem , Elzahraa A. Ahmed , Marwa Makboul , Shimaa Farghaly , Naima Mostafa , Randa A. El Zohne , Samar H. Goma","doi":"10.1016/j.reuma.2023.05.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Pulmonary involvement is a frequent and serious rheumatoid arthritis (RA) manifestation that affects 60%–80% of patients. CXCL10 is an inflammatory chemokine that regulates different biological responses, such as chemotaxis, angiogenesis, and inflammation.</p></div><div><h3>Aim</h3><p>This study aimed to identify the role of CXCL10 as a peripheral blood marker of RA-ILD and its correlation with disease activity.</p></div><div><h3>Patients and methods</h3><p><span>This cross-sectional study included 73 patients with RA (33 with </span>ILD and 40 without ILD). Pulmonary function tests and high-resolution computed tomography were performed. Blood samples were taken for complete blood count and blood chemistry analysis, and human interferon-inducible protein 10 (IP-10/CXCL10) level. Statistical Package for the Social Sciences (version 22) was used for all statistical calculations.</p></div><div><h3>Results</h3><p>The serum CXCL10 level and patient age (<em>r</em> <!-->=<!--> <!-->.393, <em>p</em> <!-->=<!--> <!-->.024), disease duration (<em>r</em> <!-->=<!--> <!-->.756, <em>p</em> <!--><<!--> <!-->0.001), erythrocyte sedimentation rate (<em>r</em> <!-->=<!--> <!-->.516, <em>p</em> <!-->=<!--> <!-->.002), C-reactive protein (<em>r</em> <!-->=<!--> <!-->.539, <em>p</em> <!-->=<!--> <!-->.001), and rheumatoid factor (<em>r</em> <!-->=<!--> <!-->.663, <em>p</em> <!--><<!--> <!-->.001) revealed a significant positive correlation. Furthermore, the Modified Health Assessment Questionnaire (<em>r</em> <!-->=<!--> <!-->−.418, <em>p</em> <!-->=<!--> <!-->.015) revealed a significant negative correlation. Patients with RA-ILD show significantly higher CXCL10 than those without ILD (<em>p</em> <!--><<!--> <!-->.001).</p></div><div><h3>Conclusion</h3><p>CXCL10 is a useful RA disease activity biomarker and is an RA-ILD-sensitive biomarker, also CXCL10 is a significant predictor for development of RA-ILD.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CXCL10 as a biomarker of interstitial lung disease in patients with rheumatoid arthritis\",\"authors\":\"Yasmine S. Makarem , Elzahraa A. Ahmed , Marwa Makboul , Shimaa Farghaly , Naima Mostafa , Randa A. El Zohne , Samar H. Goma\",\"doi\":\"10.1016/j.reuma.2023.05.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Pulmonary involvement is a frequent and serious rheumatoid arthritis (RA) manifestation that affects 60%–80% of patients. CXCL10 is an inflammatory chemokine that regulates different biological responses, such as chemotaxis, angiogenesis, and inflammation.</p></div><div><h3>Aim</h3><p>This study aimed to identify the role of CXCL10 as a peripheral blood marker of RA-ILD and its correlation with disease activity.</p></div><div><h3>Patients and methods</h3><p><span>This cross-sectional study included 73 patients with RA (33 with </span>ILD and 40 without ILD). Pulmonary function tests and high-resolution computed tomography were performed. Blood samples were taken for complete blood count and blood chemistry analysis, and human interferon-inducible protein 10 (IP-10/CXCL10) level. Statistical Package for the Social Sciences (version 22) was used for all statistical calculations.</p></div><div><h3>Results</h3><p>The serum CXCL10 level and patient age (<em>r</em> <!-->=<!--> <!-->.393, <em>p</em> <!-->=<!--> <!-->.024), disease duration (<em>r</em> <!-->=<!--> <!-->.756, <em>p</em> <!--><<!--> <!-->0.001), erythrocyte sedimentation rate (<em>r</em> <!-->=<!--> <!-->.516, <em>p</em> <!-->=<!--> <!-->.002), C-reactive protein (<em>r</em> <!-->=<!--> <!-->.539, <em>p</em> <!-->=<!--> <!-->.001), and rheumatoid factor (<em>r</em> <!-->=<!--> <!-->.663, <em>p</em> <!--><<!--> <!-->.001) revealed a significant positive correlation. Furthermore, the Modified Health Assessment Questionnaire (<em>r</em> <!-->=<!--> <!-->−.418, <em>p</em> <!-->=<!--> <!-->.015) revealed a significant negative correlation. Patients with RA-ILD show significantly higher CXCL10 than those without ILD (<em>p</em> <!--><<!--> <!-->.001).</p></div><div><h3>Conclusion</h3><p>CXCL10 is a useful RA disease activity biomarker and is an RA-ILD-sensitive biomarker, also CXCL10 is a significant predictor for development of RA-ILD.</p></div>\",\"PeriodicalId\":47115,\"journal\":{\"name\":\"Reumatologia Clinica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2023-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reumatologia Clinica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1699258X2300133X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia Clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699258X2300133X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
CXCL10 as a biomarker of interstitial lung disease in patients with rheumatoid arthritis
Introduction
Pulmonary involvement is a frequent and serious rheumatoid arthritis (RA) manifestation that affects 60%–80% of patients. CXCL10 is an inflammatory chemokine that regulates different biological responses, such as chemotaxis, angiogenesis, and inflammation.
Aim
This study aimed to identify the role of CXCL10 as a peripheral blood marker of RA-ILD and its correlation with disease activity.
Patients and methods
This cross-sectional study included 73 patients with RA (33 with ILD and 40 without ILD). Pulmonary function tests and high-resolution computed tomography were performed. Blood samples were taken for complete blood count and blood chemistry analysis, and human interferon-inducible protein 10 (IP-10/CXCL10) level. Statistical Package for the Social Sciences (version 22) was used for all statistical calculations.
Results
The serum CXCL10 level and patient age (r = .393, p = .024), disease duration (r = .756, p < 0.001), erythrocyte sedimentation rate (r = .516, p = .002), C-reactive protein (r = .539, p = .001), and rheumatoid factor (r = .663, p < .001) revealed a significant positive correlation. Furthermore, the Modified Health Assessment Questionnaire (r = −.418, p = .015) revealed a significant negative correlation. Patients with RA-ILD show significantly higher CXCL10 than those without ILD (p < .001).
Conclusion
CXCL10 is a useful RA disease activity biomarker and is an RA-ILD-sensitive biomarker, also CXCL10 is a significant predictor for development of RA-ILD.
期刊介绍:
Una gran revista para cubrir eficazmente las necesidades de conocimientos en una patología de etiología, expresividad clínica y tratamiento tan amplios. Además es La Publicación Oficial de la Sociedad Española de Reumatología y del Colegio Mexicano de Reumatología y está incluida en los más prestigiosos índices de referencia en medicina.